A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-11-14
DOI
10.3389/fimmu.2022.1027449
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Copper induces cell death by targeting lipoylated TCA cycle proteins
- (2022) Peter Tsvetkov et al. SCIENCE
- A Novel Cuproptosis-Related Prognostic Gene Signature and Validation of Differential Expression in Clear Cell Renal Cell Carcinoma
- (2022) Zilong Bian et al. Genes
- A novel Cuproptosis-related LncRNA signature to predict prognosis in hepatocellular carcinoma
- (2022) Genhao Zhang et al. Scientific Reports
- Comprehensive Analysis of Cuproptosis-Related Genes in Immune Infiltration and Prognosis in Melanoma
- (2022) Haozhen Lv et al. Frontiers in Pharmacology
- A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA
- (2022) Mingyi Yang et al. Frontiers in Immunology
- Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma
- (2022) Yun Chen Frontiers in Genetics
- Cuproptosis-Related lncRNAs are Biomarkers of Prognosis and Immune Microenvironment in Head and Neck Squamous Cell Carcinoma
- (2022) Liuqing Yang et al. Frontiers in Genetics
- Cuproptosis-Associated lncRNA Establishes New Prognostic Profile and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma
- (2022) Shengxian Xu et al. Frontiers in Genetics
- Pan-cancer analyses confirmed the cuproptosis-related gene FDX1 as an immunotherapy predictor and prognostic biomarker
- (2022) Chi Zhang et al. Frontiers in Genetics
- Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma
- (2022) Miaorong Xu et al. Frontiers in Oncology
- Cuproptosis-Related Gene – SLC31A1, FDX1 and ATP7B – Polymorphisms are Associated with Risk of Lung Cancer
- (2022) Yuhui Yun et al. Pharmacogenomics & Personalized Medicine
- The inhibitive effects of proteasome inhibitor MG-132 on pterygium fibroblasts in vitro and the potential key regulators involved
- (2021) Dandan Zhao et al. LIFE SCIENCES
- A tandem activation of NLRP3 inflammasome induced by copper oxide nanoparticles and dissolved copper ion in J774A.1 macrophage
- (2021) Xiaoqi Tao et al. JOURNAL OF HAZARDOUS MATERIALS
- The Immune Heterogeneity Between Pulmonary Adenocarcinoma and Squamous Cell Carcinoma: A Comprehensive Analysis Based on lncRNA Model
- (2021) Tao Yan et al. Frontiers in Immunology
- m6A-Related lncRNA to Develop Prognostic Signature and Predict the Immune Landscape in Bladder Cancer
- (2021) Zuwei Li et al. Journal of Oncology
- Targets for Therapy of Bladder Cancer
- (2020) Christof Seidl SEMINARS IN NUCLEAR MEDICINE
- Thymoquinone suppresses invasion and metastasis in bladder cancer cells by reversing EMT through the Wnt/β-catenin signaling pathway
- (2020) Mengzhao Zhang et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Treatment of muscle‐invasive and advanced bladder cancer in 2020
- (2020) Vaibhav G. Patel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy
- (2020) Vitaly Chasov et al. Frontiers in Oncology
- Bladder Cancer
- (2020) Andrew T. Lenis et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Multifaceted Roles of Copper in Cancer: A Trace Metal Element with Dysregulated Metabolism, but Also a Target or a Bullet for Therapy
- (2020) Pierre Lelièvre et al. Cancers
- Role of lncRNA LUCAT1 in cancer
- (2020) Ce Xing et al. BIOMEDICINE & PHARMACOTHERAPY
- Wnt signalling pathway in bladder cancer
- (2020) Guanlin Wu et al. CELLULAR SIGNALLING
- HDAC inhibitors Tubastatin A and SAHA affect parasite cell division and are potential anti-Toxoplasma gondii chemotherapeutics
- (2020) Carlla Assis Araujo-Silva et al. International Journal for Parasitology-Drugs and Drug Resistance
- PPARγ inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells
- (2019) Songtao Cheng et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Tubastatin�A, an inhibitor of HDAC6, enhances temozolomide‑induced apoptosis and reverses the malignant phenotype of glioblastoma cells
- (2019) Alejandro Urdiciain et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data
- (2019) Francesca Finotello et al. Genome Medicine
- The pan‐cancer mutational landscape of the PPAR pathway reveals universal patterns of dysregulated metabolism and interactions with tumor immunity and hypoxia
- (2019) Wai Hoong Chang et al. Annals of the New York Academy of Sciences
- lncRNA TUC338 is a potential diagnostic biomarker for bladder cancer
- (2019) Gang Li et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- An EMT‐related gene signature for the prognosis of human bladder cancer
- (2019) Rui Cao et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- The global burden of urinary bladder cancer: an update
- (2019) Anke Richters et al. WORLD JOURNAL OF UROLOGY
- The classic metal-sensing transcription factor MTF1 promotes myogenesis in response to copper
- (2019) Cristina Tavera-Montañez et al. FASEB JOURNAL
- Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer
- (2019) Changhao Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro
- (2018) Jennifer Bourn et al. Drug Design Development and Therapy
- LncRNA as a diagnostic and prognostic biomarker in bladder cancer: a systematic review and meta-analysis
- (2018) Jing Quan et al. OncoTargets and Therapy
- Bladder Cancer Survivorship
- (2018) Sumeet K. Bhanvadia Current Urology Reports
- Immunotherapy in Bladder Cancer
- (2016) Monali Vasekar et al. Current Molecular Pharmacology
- Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines
- (2014) Paul Geeleher et al. GENOME BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started